Beacon Equity issues Trading Outlook for Repros Therapeutics Inc.
The report includes financial, comparative and investment analyses, and pertinent industry information you need to know to make an educated investment decision.
(EMAILWIRE.COM, September 17, 2009 ) DALLAS, Texas - BeaconEquity.com announces an investment report featuring Repros Therapeutics Inc. (NASDAQ: RPRX).
The investment report on Repros Therapeutics Inc. (NASDAQ: RPRX) should be of particular interest to comparable companies: Gilead Sciences Inc. (NASDAQ: GILD), Biogen Idec Inc. (NASDAQ: BIIB), Genzyme Corp. (NASDAQ: GENZ) and Life Technologies Corp. (NASDAQ: LIFE).
It is available at: http://www.beaconequity.com/i/RPRX
Get our alerts BEFORE the rest of the market. Follow us on Twitter: http://twitter.com/BeaconEquity
Repros Therapeutics Inc. (RPRX) is a development-stage biopharmaceutical company focused on the development of oral small molecule drugs for unmet medical needs. The Company's principal drug, Proellex, is a selective blocker of the progesterone receptor for the treatment of uterine fibroids, anemia associated with excessive menstrual bleeding relating to uterine fibroids, or anemia associated with uterine fibroids and endometriosis. The second product candidate, Androxal, is a single isomer of clomiphene citrate and an orally active small molecule compound.
Message Board Search for RPRX: http://www.boardcentral.com/boards/RPRX
In the report, the analyst notes:
“On August 3, 2009, RPRX announced that it was suspending its drug Proellex’s clinical trials based in part on ‘the occurrence of clinically significant increases in liver enzymes.’ As a result of the voluntary suspension of Proellex trials, the Company announced it was at risk of bankruptcy unless it received new financing. As a result of this news, the price of RPRX stock declined sharply from the previous day’s closing price of $2.53, to close on August 3, 2009, at $1.31 per share or approximately 48% on extremely high trading volume of more than 7.4 million shares.
“However, shortly after this announcement, the Company reported a definitive agreement with a single institutional investor to sell 1.5 million shares of its common stock at $0.65 per share for gross proceeds of approximately $1.0 million.”
To read the entire report visit: http://www.beaconequity.com/i/RPRX
See what investors are saying about these stocks at: http://www.stockhideout.com/
BeaconEquity.com is one of the industry's largest small-cap report providers. Beacon strives to provide a balanced view of many promising small-cap companies that would otherwise fall under the radar of the typical Wall Street investor. We provide investors with an excellent first step in their research and due diligence by providing daily trading ideas, and consolidating the public information available on them. For more information on Beacon, please visit http://www.BeaconEquity.com
Beacon Equity Disclosure
DO NOT BASE ANY INVESTMENT DECISION UPON ANY MATERIALS FOUND ON THIS REPORT. We are not registered as a securities broker-dealer or an investment adviser either with the U.S. Securities and Exchange Commission (the "SEC") or with any state securities regulatory authority. We are neither licensed nor qualified to provide investment advice. Beacon nor its affiliates have a beneficial interest in the mentioned company; nor have they received compensation of any kind for any of the companies listed in this communication. The information contained in our report is not an offer to buy or sell securities.
The investment report on Repros Therapeutics Inc. (NASDAQ: RPRX) should be of particular interest to comparable companies: Gilead Sciences Inc. (NASDAQ: GILD), Biogen Idec Inc. (NASDAQ: BIIB), Genzyme Corp. (NASDAQ: GENZ) and Life Technologies Corp. (NASDAQ: LIFE).
It is available at: http://www.beaconequity.com/i/RPRX
Get our alerts BEFORE the rest of the market. Follow us on Twitter: http://twitter.com/BeaconEquity
Repros Therapeutics Inc. (RPRX) is a development-stage biopharmaceutical company focused on the development of oral small molecule drugs for unmet medical needs. The Company's principal drug, Proellex, is a selective blocker of the progesterone receptor for the treatment of uterine fibroids, anemia associated with excessive menstrual bleeding relating to uterine fibroids, or anemia associated with uterine fibroids and endometriosis. The second product candidate, Androxal, is a single isomer of clomiphene citrate and an orally active small molecule compound.
Message Board Search for RPRX: http://www.boardcentral.com/boards/RPRX
In the report, the analyst notes:
“On August 3, 2009, RPRX announced that it was suspending its drug Proellex’s clinical trials based in part on ‘the occurrence of clinically significant increases in liver enzymes.’ As a result of the voluntary suspension of Proellex trials, the Company announced it was at risk of bankruptcy unless it received new financing. As a result of this news, the price of RPRX stock declined sharply from the previous day’s closing price of $2.53, to close on August 3, 2009, at $1.31 per share or approximately 48% on extremely high trading volume of more than 7.4 million shares.
“However, shortly after this announcement, the Company reported a definitive agreement with a single institutional investor to sell 1.5 million shares of its common stock at $0.65 per share for gross proceeds of approximately $1.0 million.”
To read the entire report visit: http://www.beaconequity.com/i/RPRX
See what investors are saying about these stocks at: http://www.stockhideout.com/
BeaconEquity.com is one of the industry's largest small-cap report providers. Beacon strives to provide a balanced view of many promising small-cap companies that would otherwise fall under the radar of the typical Wall Street investor. We provide investors with an excellent first step in their research and due diligence by providing daily trading ideas, and consolidating the public information available on them. For more information on Beacon, please visit http://www.BeaconEquity.com
Beacon Equity Disclosure
DO NOT BASE ANY INVESTMENT DECISION UPON ANY MATERIALS FOUND ON THIS REPORT. We are not registered as a securities broker-dealer or an investment adviser either with the U.S. Securities and Exchange Commission (the "SEC") or with any state securities regulatory authority. We are neither licensed nor qualified to provide investment advice. Beacon nor its affiliates have a beneficial interest in the mentioned company; nor have they received compensation of any kind for any of the companies listed in this communication. The information contained in our report is not an offer to buy or sell securities.
Contact Information:
Beacon Equity
Jeff Bishop
Tel: (469)-252-3505
Email us
This is a press release. Press release distribution and press release services by EmailWire.Com: http://www.emailwire.com/us-press-release-distribution.php.
Beacon Equity
Jeff Bishop
Tel: (469)-252-3505
Email us
This is a press release. Press release distribution and press release services by EmailWire.Com: http://www.emailwire.com/us-press-release-distribution.php.
|
Private Equity, Angel Investing
Equity Alliance / Private Equity, Angel Investing, / IPO, Venture Capital & IR services / Equity Alliance International Equityallianceir.com Penny Stocks to Watch Sign up for hot penny stock picks Gains of 500%+ possible! Premiumstockpicks.com/landing/ Your text Ads & PR Text Ads plus unlimited press releases, One release featured/Day for only $575 per month. Read more on Text Ads & PR Your text Ads Here! Text Ads are only $289 per month. Ads are placed same day. More on Text Ads Advertising |